精华制药
(002349)
| 流通市值：62.37亿 | | | 总市值：63.66亿 |
| 流通股本：8.14亿 | | | 总股本：8.31亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 754,772,245.25 | 379,763,838 | 1,459,957,149.65 | 1,092,285,389.95 |
| 营业收入 | 754,772,245.25 | 379,763,838 | 1,459,957,149.65 | 1,092,285,389.95 |
| 二、营业总成本 | 563,082,590.66 | 283,381,216.65 | 1,161,319,446.31 | 853,284,673.64 |
| 营业成本 | 345,227,582.65 | 169,416,002.59 | 702,399,970.43 | 517,097,102.69 |
| 税金及附加 | 12,017,692.08 | 6,236,189.6 | 22,992,303.33 | 17,520,095.27 |
| 销售费用 | 117,193,385.18 | 65,068,369.08 | 267,361,546.48 | 203,123,914.2 |
| 管理费用 | 63,374,295 | 31,546,830.74 | 126,972,159.48 | 91,880,233.18 |
| 研发费用 | 30,208,333.06 | 14,289,948.17 | 64,986,066.45 | 43,536,583.86 |
| 财务费用 | -4,938,697.31 | -3,176,123.53 | -23,392,599.86 | -19,873,255.56 |
| 其中:利息费用 | 515,700.59 | 116,594.96 | 572,446.82 | 456,819.92 |
| 其中:利息收入 | 9,711,931.49 | 5,171,833.2 | 26,727,823.57 | 22,054,939.82 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,186,541.89 | 1,315,105.01 | 4,173,858.83 | 3,121,088.82 |
| 加:投资收益 | 1,701,868.1 | 711,451.63 | 3,572,027.3 | 1,803,269.91 |
| 资产处置收益 | 7,108.88 | - | -5,092.86 | 38,903.55 |
| 资产减值损失(新) | -4,242,760.83 | -3,634,119.94 | -10,753,818.03 | -4,927,449.1 |
| 信用减值损失(新) | -1,606,488.15 | -1,846,252.06 | -452,317.58 | -513,963.56 |
| 其他收益 | 2,035,245.5 | 1,139,145.75 | 9,113,332.55 | 3,559,198.14 |
| 四、营业利润 | 191,771,169.98 | 94,067,951.74 | 304,285,693.55 | 242,081,764.07 |
| 加:营业外收入 | 1,556,787.06 | 433,483.91 | 2,992,003.7 | 1,157,227.88 |
| 减:营业外支出 | 542,088.91 | 7,609.74 | 3,671,858.13 | 191,572.56 |
| 五、利润总额 | 192,785,868.13 | 94,493,825.91 | 303,605,839.12 | 243,047,419.39 |
| 减:所得税费用 | 27,539,587.15 | 12,744,204.55 | 41,770,280.62 | 33,494,967.65 |
| 六、净利润 | 165,246,280.98 | 81,749,621.36 | 261,835,558.5 | 209,552,451.74 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 165,246,280.98 | 81,749,621.36 | 261,835,558.5 | 209,552,451.74 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 136,125,439.12 | 65,872,510.07 | 219,284,778.83 | 176,372,682.12 |
| 少数股东损益 | 29,120,841.86 | 15,877,111.29 | 42,550,779.67 | 33,179,769.62 |
| 扣除非经常损益后的净利润 | 131,591,232.23 | 63,823,539.15 | 208,124,771.96 | 170,110,974.04 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.17 | 0.08 | 0.27 | 0.21 |
| (二)稀释每股收益 | 0.17 | 0.08 | 0.27 | 0.21 |
| 九、综合收益总额 | 165,246,280.98 | 81,749,621.36 | 261,835,558.5 | 209,552,451.74 |
| 归属于母公司股东的综合收益总额 | 136,125,439.12 | 65,872,510.07 | 219,284,778.83 | 176,372,682.12 |
| 归属于少数股东的综合收益总额 | 29,120,841.86 | 15,877,111.29 | 42,550,779.67 | 33,179,769.62 |
| 公告日期 | 2026-08-27 | 2026-04-30 | 2026-04-23 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |